Singular Health Group (ASX:SHG) EBITDA per Share: A$-0.02 (TTM As of Dec. 2025)


ASX:SHG Singular Health Group Ltd ASX:SHG
30 GF Score
Price A$0.21
GF Value A$0.11
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Singular Health Group EBITDA per Share?

Singular Health Group ASX:SHG +2.44% 30 EBITDA per Share is A$-0.02 as of Dec. 2025. GuruFocus rates ASX:SHG with a GF Score™ of 30/100 and a GF Value™ of A$0.11 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 531 Healthcare Providers & Services companies, Singular Health Group ranks better than 69.3% on this metric.

Singular Health Group's EBITDA per Share for the six months ended in Dec. 2025 was A$-0.01. Its EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.02.

During the past 3 years, the average EBITDA per Share Growth Rate was 22.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Singular Health Group's EBITDA per Share or its related term are showing as below:

ASX:SHG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 22.6   Med: 22.65   Max: 22.7
Current: 22.6

During the past 5 years, the highest 3-Year average EBITDA per Share Growth Rate of Singular Health Group was 22.70% per year. The lowest was 22.60% per year. And the median was 22.65% per year.

ASX:SHG's 3-Year EBITDA Growth Rate is ranked better than
69.3% of 531 companies
in the Healthcare Providers & Services industry
Industry Median: 9.9 vs ASX:SHG: 22.60

Singular Health Group's EBITDA for the six months ended in Dec. 2025 was A$-2.92 Mil.

During the past 3 years, the average EBITDA Growth Rate was -2.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 5 years, the highest 3-Year average EBITDA Growth Rate of Singular Health Group was -0.30% per year. The lowest was -2.30% per year. And the median was -1.30% per year.


Singular Health Group  (ASX:SHG) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Singular Health Group EBITDA per Share Related Terms


Singular Health Group EBITDA per Share Historical Data

* Premium members only.

The historical data trend for Singular Health Group's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Singular Health Group EBITDA per Share Chart

Singular Health Group Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
EBITDA per Share
-0.04 -0.06 -0.04 -0.02 -0.03

Singular Health Group Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 -0.01
ASX:SHG
30GF Score
Singular Health Group Ltd ASX:SHG
EBITDA per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Singular Health Group EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Singular Health Group's EBITDA per Share for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA per Share(A: Jun. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=-6.122/237.045
=-0.03

Singular Health Group's EBITDA per Share for the quarter that ended in Dec. 2025 is calculated as

EBITDA per Share(Q: Dec. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=-2.918/309.386
=-0.01

EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of A$-0.02 mean?
Singular Health Group (ASX:SHG) has a EBITDA per Share of A$-0.02 as of Dec. 2025. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Singular Health Group and its competitors. According to the industry distribution chart, Singular Health Group ranks #163 out of 531 companies in the Healthcare Providers & Services industry, placing it in the top 30.7%.
Is Singular Health Group's EBITDA per Share too high?
Singular Health Group's current EBITDA per Share is A$-0.02. Based on the distribution chart, Singular Health Group ranks #163 out of 531 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Singular Health Group has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Singular Health Group's EBITDA per Share compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Singular Health Group ranks #163 out of 531 companies for EBITDA per Share. This puts Singular Health Group in the upper half of its industry. The industry median EBITDA per Share is 9.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Healthcare Providers & Services company?
The median EBITDA per Share among Healthcare Providers & Services companies is 9.90, based on 531 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Singular Health Group and its competitors. For the Healthcare Providers & Services industry, the median EBITDA per Share is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Singular Health Group's current EBITDA per Share is A$-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Singular Health Group stock overvalued right now?
Based on GuruFocus' analysis, Singular Health Group (ASX:SHG) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.11, compared to a current price of A$0.21 — trading 90.9% above its estimated fair value. The current EBITDA per Share is A$-0.02. Singular Health Group's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For Singular Health Group (ASX:SHG), the current EBITDA per Share is A$-0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Singular Health Group (ASX:SHG) Overvalued in 2026?

Based on GuruFocus' analysis, Singular Health Group stock appears to be overvalued. The current stock price of A$0.21 is trading 90.9% above its estimated GF Value™ of A$0.11. GuruFocus considers Singular Health Group to be Significantly Overvalued.

Key valuation signals for ASX:SHG:

  • EBITDA per Share: A$-0.02
  • GF Value™: A$0.11 vs. price of A$0.21 (90.9% above fair value)
  • GF Score™: 30/100 with 2 warning signs

No single metric tells the full story. See the ASX:SHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Singular Health Group Business Description

Address E3 and E4, 661 Newcastle Street, Leederville, WA, AUS, 6007
Singular Health Group Ltd provides medical software solutions. The company's business segment is the provision of Volume Rendering Platform (VRP) software, providing 3D printing services and 3D machine sales. It operates in one segment, which is the provision and development of medical technology within Australia.
30GF Score

Get the complete analysis for ASX:SHG

EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.21
Price
A$0.11
GF Value